Nasus Pharma's CEO is Dan Teleman, appointed in Jan 2025, has a tenure of 1.42 years. total yearly compensation is $562.16K, comprised of 42.3% salary and 57.7% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $70.02K. The average tenure of the management team and the board of directors is 7.4 years and 1.1 years respectively.
Key information
Dan Teleman
Chief executive officer
US$562.2k
Total compensation
CEO salary percentage
42.27%
CEO tenure
1.4yrs
CEO ownership
0.2%
Management average tenure
7.4yrs
Board average tenure
1.1yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Dan Teleman's remuneration changed compared to Nasus Pharma's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
US$562k
US$238k
-US$6m
Compensation vs Market: Dan's total compensation ($USD562.16K) is about average for companies of similar size in the US market ($USD647.34K).
Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.
CEO
Dan Teleman (53 yo)
1.4yrs
Tenure
US$562,163
Compensation
Mr. Dan Teleman, MBA M.Sc., is the Chief Executive Officer at Nasus Pharma Ltd. since January 7, 2025 and serves as its Director since September 3, 2025. Mr. Teleman joined Nasus Pharma in January 2025.He...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Ehud Gilboa
Co-Founder & Executive Chairman
7.4yrs
US$545.08k
16.39% $ 5.6m
Dan Teleman
CEO & Director
1.4yrs
US$562.16k
0.21% $ 70.0k
Dalia Megiddo
Co-Founder
7.4yrs
US$488.27k
16.13% $ 5.5m
Eyal Rubin
CFO & Executive VP
less than a year
US$80.50k
no data
Yifat Bar
Vice President of Administration & Human Resources
no data
no data
no data
Galia Kryaz
Director of CMC & Product Development
7.4yrs
no data
1.47% $ 498.0k
7.4yrs
Average Tenure
59yo
Average Age
Experienced Management: NSRX's management team is seasoned and experienced (7.4 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Ehud Gilboa
Co-Founder & Executive Chairman
7.4yrs
US$545.08k
16.39% $ 5.6m
Dan Teleman
CEO & Director
less than a year
US$562.16k
0.21% $ 70.0k
Dalia Megiddo
Co-Founder
7.1yrs
US$488.27k
16.13% $ 5.5m
Sharon Shacham
Independent Director
less than a year
no data
no data
Ronnie Hershman
Independent Director
6.1yrs
no data
0% $ 0
Isaac Israel
Independent Director
less than a year
no data
no data
David Silberman
Independent Director
less than a year
no data
no data
David Fleischer
Advisory Board Member
no data
no data
no data
Yuval Tal
Advisory Board Member
no data
no data
no data
Regina Scherliess
Advisory Board Member
no data
no data
no data
Jonathan Bernstein
Advisory Board Member
no data
no data
no data
Moshe Ben-Shoshan
Advisory Board Member
1.4yrs
no data
no data
1.1yrs
Average Tenure
54.5yo
Average Age
Experienced Board: NSRX's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/10 22:53
End of Day Share Price
2026/06/10 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nasus Pharma Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.